Investors | OTC Biotech

OTC Biotechnologies, LLC, (OTC BioTech) is a wholly-owned subsidiary of Operational Technologies Corporation. The OpTech Biotechnology Research Division that later became OTC BioTech was established as a self-supporting R&D activity primarily using funding obtained through the SBIR Program process.

Latest News

  • 2014 - Awarded a Phase 1 SBIR from the Centers for Disease Control (CDC; $150K) entitled “Aptamers to Detect Fungi in Formalin-Fixed Sections.” Contract No. 200-2014-M-60961.
  • 2014 - Awarded a Phase 1 SBIR from DARPA ($150K with Option Phase) entitled “Universal Antivenom DNA Aptamer Dendrimers.” Contract No. W911NF-14-P-0037.
  • 2014 - Awarded a Task Order Contract from Naval Medical Research Command (NMRC; $100K) entitled “Improved Rickettsial Aptamer Antigens and their Use in Fluorescence Assays.” Contract No. N32398-14-P-0340.
  • 2013 - Awarded a National Cancer Institute (NCI) Phase 1 SBIR Contract ($200K) entitled “DNA Aptamer-Based Peptide Enrichment for Proteomics.” Contract No. HHSN261201300075C.
  • 2013 - Awarded a USDA Phase 1 SBIR ($100K) entitled “Fluorescent DNA Aptamer Test Strips for More Sensitive and Rapid Assessment of Food Safety.” Grant No. 2013-33610-20873.
  • 2012 - OTC Biotech contributes 3 chapters and edits a new international book entitled Biomedical Applications of Aptamers available 4Q of 2012 from Nova Science.
    read more
  • 2012 - OTC Biotech wins $150,000 Phase 1 SBIR grant (No. 1 R43 GM101712-01) from NIH to develop analgesic aptamers against oxidized linoleic acid metabolites in conjunction with Prof. Ken Hargreaves of the Univ. of Texas Health Sciences Center in San Antonio.
  • 2011 - Dr. Bruno speaks on aptamers to detect recombinant human growth hormone for the U.S. Anti-Doping Agency (USADA) in London and wins $160,000 follow on grant from the World Anti-Doping Agency (WADA)
    read more


To control the direction of OTC BioTech’s research efforts and the ability to better control the timing of expansion for our novel technologies, OTC BioTech adopted a business strategy to “spin-off” separate companies as research progressed and commercially attractive areas were discovered. Each new biotechnology “spin-off” company receives an exclusive license agreement with the technical progress made thus far, including the patented IP of OTC BioTech.

This decision also allowed the “spin-off company” to be a manufacturer through outsourcing to contract manufacturers enabling marketing and sales of products to maximize potential and value to the newly-formed company and providing an attractive ROI to that company’s stockholders.